Hypertension-linked mutation of &#945;-adducin increases CFTR surface expression and activity in HEK and cultured rat distal convoluted tubule cells by A. Mondini et al.
Hypertension-Linked Mutation of a-Adducin Increases
CFTR Surface Expression and Activity in HEK and
Cultured Rat Distal Convoluted Tubule Cells
AnnaMondini1., Francesca Sassone1., Davide Antonio Civello1, Maria Lisa Garavaglia1, Claudia Bazzini1,
Simona Rodighiero2, Valeria Vezzoli1, Fabio Conti3, Lucia Torielli3, Giovanbattista Capasso4,
Markus Paulmichl5, Giuliano Meyer1*
1Department of Life Sciences, Universita` degli Studi di Milano, Milano, Italy, 2 Fondazione Filarete, Milano, Italy, 3 Prassis Research Institute, Sigma Tau, Settimo M.se, Italy,
4Department of Internal Medicine, Second University of Napoli, Napoli, Italy, 5 Institut of Pharmacology and Toxicology, Paracelsus Medical University, Salzburg, Austria
Abstract
The CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) activity and localization are influenced by the
cytoskeleton, in particular by actin and its polymerization state. In this study we investigated whether the expression of the
hypertensive mutations of a-adducin (G460W-S586C in humans, F316Y in rats), an actin capping protein, led to a functional
modification of CFTR activity and surface expression. The experiments were performed on HEK293 T cells cotransfected with
CFTR and the human wild type (WT) or G460W mutated a-adducin. In whole-cell patch-clamp experiments, both the CFTR
chloride current and the slope of current activation after forskolin addition were significantly higher in HEK cells
overexpressing the G460W adducin. A higher plasma membrane density of active CFTR channels was confirmed by cell-
attached patch-clamp experiments, both in HEK cells and in cultured primary DCT cells, isolated from MHS (Milan
Hypertensive Strain, a Wistar rat (Rattus norvegicus) hypertensive model carrying the F316Y adducin mutation), compared
to MNS (Milan Normotensive Strain) rats. Western blot experiments demonstrated an increase of the plasma membrane
CFTR protein expression, with a modification of the channel glycosylation state, in the presence of the mutated adducin. A
higher retention of CFTR protein in the plasma membrane was confirmed both by FRAP (Fluorescence Recovery After
Photobleaching) and photoactivation experiments. The present data indicate that in HEK cells and in isolated DCT cells the
presence of the G460W-S586C hypertensive variant of adducin increases CFTR channel activity, possibly by altering its
membrane turnover and inducing a retention of the channel in the plasmamembrane. Since CFTR is known to modulate the
activity of many others transport systems, the increased surface expression of the channel could have consequences on the
whole network of transport in kidney cells.
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Introduction
Adducins (a, b, and c) are cytoskeletal F-actin end-capping
proteins that play a role in restricting actin filament length [1], by
binding directly to F-actin and bundling actin filaments [2].
Furthermore they promote the binding of spectrin to actin [3,4],
thus regulating the assembly of the subcortical cytoskeletal
membrane network [5]. In epithelial cells, adducin is associated
with the spectrin-based membrane skeleton and spectrin-adducin-
ankyrin complexes link membranes to the actin cytoskeleton [6].
In this cell type adducins are expecially abundant at cell-cell
contact sites [7] and are also present in the clathrin-coated vesicle
(CCV) compartment, associated with clathrin [8].
Both in a cell free system and in a kidney cell line, a-adducin
mutations (F316Y and G460W-S586C in rats and humans
respectively) interfere with actin assembly and polymerization,
leading to a higher final level of filamentous actin [9]. These
adducin mutations have also been found to be significantly related
to Na+-sensitive hypertension development by influencing cation
and anion transport mechanisms in renal epithelia [10–13].
In renal epithelial cells, the transfection with mutated (F316Y)
rat a-adducin induces an increase in Na+/K+ pump activity [9].
This upregulation is in part depending on a decrease of pump
endocytosis from the basolateral membrane [8], likely because of
increased adaptor protein 2 (AP-2) phosphorylation [14]. Further-
more in vitro, mutated adducin variants have been shown to
directly activate the Na+/K+-ATPase, by accelerating the rate of
conformational change [13] and increasing Src-dependent Na+/
K+-ATPase phosphorylation and activity [15].
Na+/K+-ATPase is not the only renal transport system affected
by mutations of the adducin gene. In Thick Ascending Limb
(TAL) and Distal Convoluted Tubule (DCT) cells of Milan
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Hypertensive rats (MHS), a model system of Na+-sensitive
hypertension bearing the F316Y adducin mutation [16], an
increase of the activity and/or expression of NKCC2 [17,18],
NCC (Na+-Cl2 cotransporter), and of ClC-K chloride channels
has been observed [11], suggesting that adducin mutations can
directly or indirectly impact on several Na+ and Cl2 transport
systems, especially in the distal segments of the nephron.
CFTR is one of the chloride channels expressed in the kidney.
Its expression and functional activity has been demonstrated in
several nephron tracts such as DCT, cortical collecting duct (CCT)
and inner medullary collecting duct [19]. Despite the broad
distribution, the role of CFTR in the kidney remains uncertain as
there is no major disruption of renal function in cystic fibrosis
patients [20], apart from a reduced renal excretion of NaCl.
Nevertheless, CFTR is also a regulatory protein influencing the
activity and localization of other membrane proteins as well and
other renal Cl2 and Na+ channels and transporters could be
influenced by CFTR [19,21,22], as observed in several cell types
[23]. In proximal tubular cells, CFTR is present in intracellular
vesicles along both the exocytic and the endocytic pathways,
where by ensuring the chloride conductance dissipating the
potential difference originated by the V-ATPase active H+-
transport, it participates to endosomal acidification and therefore
to receptor-mediated protein uptake by PT (proximal tubule) cells
[24,25].
CFTR channel activity and expression are regulated, besides
other several intracellular factors like PKA, also by the
cytoskeleton. Changes in actin filament organization modulate
CFTR channel activity by a mechanism entailing a direct
interaction between actin filaments and CFTR [26]. Further-
more CFTR intracellular dynamics and plasmamembrane
expression are affected by cytoskeletal proteins. Efficient in-
ternalization of CFTR requires actin polymerization and
association with the actin-binding motor protein Myosin VI
[27,28]. The surface localization of CFTR is stabilized also by
other interacting proteins, such as the multidomain cytoskeletal
protein filamin [29] and the PDZ-containing adaptor molecule
NHERF1/EBP50, that connects CFTR to the microtubules
network [30] and to the cortical actin cytoskeleton [31]. CFTR
surface expression is also regulated through its trafficking and
endocytotic recycling. It associates with SNARE proteins
(syntaxin 1A, SNAP23) and endocytic adaptors such as AP-2,
undergoing clathrin-mediated endocytosis [23,32]. A balance
between cytoskeletal tethering and capture by the endocytic
machinery may be crucial to maintain a sufficient population of
CFTR at the cell surface.
Since the hypertensive adducin variants influence the
cytoskeleton and the AP-2 mediated endocytosis, we investigated
whether CFTR could be influenced by these adducin mutations
too. We performed electrophysiological, biochemical and
fluorescence experiments to evaluate the influence of the
hypertension-linked human G460W-S586C adducin variant
(G460W adducin) on CFTR activity, expression and trafficking.
These experiments demonstrated that this adducin mutation can
actually modulate CFTR activity and surface expression in
HEK 293 cells. To explore the physiological implications of
adducin influence on CFTR channel activity, we performed
additional experiments on Milan Hypertensive Rats (MHS) rats
DCT primary cultured cells. Patch-clamp experiments demon-
strated a higher channel activity in MHS rat cells compared to
the corresponding normotensive strain (MNS), thus suggesting
a possible role for adducin as a regulator of CFTR channel
activity also in vivo.
Materials and Methods
cDNA Constructs
cDNA encoding human CFTR was subcloned from pcDNA3,
kindly provided from M. Conese (Universita` degli Studi, Foggia),
into the following expression vectors: pIRES2-EGFP (Clontech)
for patch-clamp experiments, pEYFP-N and pEYFP-C (Clontech)
for FRET and FRAP experiments, PAGFP for photoactivation
experiments. cDNA encoding for human WT or G460W adducin
was subcloned from pcDNA3.1, kindly provided by M.G. Tripodi
(Prassis, Sigma Tau, Milan), into pECFP-C and pECFP-N
(Clontech) for FRET, FRAP and photactivation experiments. In
the case of FLAG coimmunoprecipitation experiments, a FLAG
tag (sequence: DYKDDDDK) was inserted by mutagenesis
(performed with QuikChange Site-Directed Mutagenesis Kit,
Stratagene) at the C-t of adducin in the pcDNA3.1 vector, before
the STOP codon. HA-immunopreciptation experiments were
performed by using the pcDNA3.1-HA-adducin vector [8]. All
cDNA constructs were confirmed by sequencing.
Cell Culture and Transfection
Primary culture of DCT cells. Hypertensive male MHS
Wistar rats (2 months old; body weight, 350 g) and corresponding
control MNS were used. To obtain primary culture of DCT cells,
DCT tubules were microdissected from the whole kidney
according to a previously described method [11]. The experiments
are in accordance with the Italian guidelines for laboratory
animals (Protocol Nu 5/2008). All surgery was performed under
Avertin (2, 2, 2-Tribromoethanol) anesthesia, and all efforts were
made to minimize suffering.
HEK cells. HEK293 cells stably transfected with WT (NU12
cells) or G460W (HU33 cells) a-adducin were kindly provided by
Prassis, Sigma Tau, Milan [8]. Human embryonic kidney (HEK)
293T cells, NU12 and HU33 were cultured in MEM, 1% FBS and
transiently transfected for FRET, Western blot or patch-clamp
experiments as previously reported [33]. The maintenance of the
expression of adducin was routinely assessed by Western blot and
immunocytochemistry, as shown in Figure S1.
Patch-clamp Experiments
Patch-clamp experiments were performed on NU12 (HEK cells
stably transfected with the human wild-type adducin) and HU33
cells (expressing the G460W mutation) transiently transfected with
a human CFTR expressing bicistronic vector (pIRES2-EGFP-
CFTR), that allows to express both CFTR and EGFP (Enhanced
Green Fluorescent Protein) as two separate proteins. The pIRES2-
EGFP vector, expressing only EGFP, was used as control. Adducin
and CFTR expression has been verified by Western blot. For
whole-cell experiments the pipette solution contained (mM)
140 CsCl, 10 tetraethylammonium chloride, 0.5 EGTA, 2 MgCl2,
2 Mg–ATP, 5 glucose and 5 HEPES (pH 7.2, 320 mOsm) and the
bath solution contained (mM) 145 NaCl, 4 CsCl,1 CaCl2, 1
MgCl2, 10 glucose and 10 HEPES (pH 7.4), 324 mOsm. All
experiments were performed at room temperature (22–25uC).
Pipettes were pulled from borosilicate glass and had resistances of
3–5 MV after fire polishing. Seal resistances were typically
between 3 and 10 GV. After establishing the whole-cell configu-
ration, CFTR was activated by adding 10 mmol/L forskolin.
Currents were recorded using a EPC9 amplificator (HEKA,
Germany) and low-pass filtered at 1 kHz. Mean currents were
normalized as current densities (pA/pF). Cell capacitance was not
statistically different in HU33 and NU12 cells (NU12:
17.761.3 pF, n= 14; HU33: 19.661.0 pF, n= 12). Forskolin
activation time course analysis was performed after complete
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solution change in the chamber (within 30 s). The current
amplitude was measured at a constant potential of +40 mV every
15 s until a steady state was obtained. The forskolin activation
time course was fitted, using GraphPad Prism v5 software, with
a sigmoidal function:
Y~
Yminz Ymax{Yminð Þ
1ze:st50{x
Where Ymin and Ymax are the minimum and the maximum Y
values (pA/pF) respectively, s is the rate constant for the rise of
the sigmoidal function, and t50 is the time interval from the start to
the inflection point of the sigmoidal function.
For cell-attached patch-clamp experiments the bath solution
was an HBSS solution (Sigma, Italy), buffered at pH 7.4 with
10 mM Hepes, 304 mOsm. The micropipette solution (cell-
attached and inside-out configurations) contained (mM): 115 N-
Methyl Glucamine Cl, 30 TEACl, 2 CaCl2, 1 MgCl2, 10 HEPES
(pH 7.4), 309 mOsm. All experiments were performed at room
temperature (22–25uC). The patch pipette resistance was 5–
10 MV, and seal resistance was 5–10 GV. Currents were recorded
using a EPC9 amplificator (HEKA, Germany), digitized at 5 kHz
and low-pass filtered at 0.2 kHz. The bath was earthed with an
Ag/AgCl electrode immersed in the bath solution. Potential
differences were expressed as overall potential differences,
considering the junction potential, the holding potential, and the
cell membrane potential, measured to be about -30 mV (current
clamp experiments). Data analysis was performed by Bruxton Tac
program. For single-channel studies of CFTR, voltage was stepped
from 2135 to +65 mV (overall potential) in 20 mV increments of
20 s duration. Slope conductance was calculated by dividing
unitary current by the overall potential differences. The number of
channels in a membrane patch was determined from the
maximum number of simultaneous channel openings observed
during the course of an experiment, as described [34]. For open
probability (Po) analyses, lists of open and closed times were
created using a half-amplitude crossing criterion for event
detection. Transitions ,3.32 ms in duration were excluded from
the analyses, as filter risetime (tr = 0.3321/fc with fc = filter corner
frequency) was 1.65 ms. As we usually observed more than one
channel in a patch, the open probability of the single channel (Po)
was calculated as previously reported [27]. Ramp I-V relationships
were obtained by averaging currents generated by 10 ramps of
voltage each of 2-s duration; holding voltage was 0 mV. All
records were leakage corrected: basal currents with no active
CFTR Cl2 channels were subtracted from those showing CFTR
activity before averaging subtracted currents to generate the
ensemble ramp I-V relationship of CFTR Cl2 currents [11].
Western Blot
CFTR expression was assessed using the monoclonal anti-
CFTR 24.1 antibody (R&D System) on lysates obtained from
HEK293 clones stably expressing HA-tagged a-adducin WT
(clone NU12) or G460W (clone HU33) and transiently expressing
CFTR. Transfection efficiency has been verified by immunoflu-
orescence and by the luciferase reporter methods (see supplemen-
tal material) and, with both methods, it was not significantly
different between HU33 and NU12 cells (Figure S2). HU33 and
NU12 cells transiently expressing CFTR were lysed in Triton lysis
buffer (TLB: 1% Triton, 25 mmol/l Tris pH 7.4, 150 mmol/l
NaCl) and protease inhibitors, (Complete EDTA-free Protease
Inhibitor Cocktail (Roche). The lysate was spinned at 20000 g for
20 min and the supernatant saved. The isolation of the plasma
membrane proteins was performed with the Plasma Membrane
Protein Extraction Kit (MBL International Corporation), follow-
ing manufacturer instructions. The reliability of plasma membrane
separation has been verified by confirming the enrichment in the
plasmamembrane fraction of cadherin, a plasmamembrane mark-
er, compared to calreticulin, an endoplasmic reticulum marker
(see Text S1 and Figure S2). Protein concentration in the samples
was quantified by the Bradford assay (Biorad). All protein extracts
were heated at 37uC for 20 minutes in SDS-PAGE solubilising
buffer (57.85 mmol/l Tris HCl, 10% Glycerol, 2% SDS, 0.004%
Bromophenol blue, pH 6.8) containing 7.5% Dithiothreitol, and
microfuged for 1 minute. 100 mg of total proteins or 20 mg of
membrane proteins were loaded in each lane and separated by
SDS-PAGE-electrophoresis on a 6.5% polyacrylamide gel at
100 V for 2 hour. Following electrophoresis, proteins were
transferred overnight onto a PVDF (Polyvinylidene Fluoride)
membrane. After blocking in blocking buffer 1 (PBS pH 7.4, 2%
semi-skimmed milk powder, 0.05% Tween-20) for 2 hours at room
temperature, the membrane was incubated with the anti-CFTR
24.1 (R&D Systems) diluted 1:1000 in the blocking buffer at 4uC
overnight, followed, after several washing steps, by the secondary
HRP-conjugated antibody (1:10000) at room temperature for
1 hour. Detection was performed with the Immobilon ECL system
(Millipore). In all other cases, after transfer, the membrane was
exposed to blocking buffer 2 (PBS pH 7.4, 5% semi-skimmed milk
powder, 0.1% Tween-20) for 1 hour at room temperature. In case
of reprobing of the blot, the membrane was first exposed to
a stripping solution (0.05 M glicine and 1% SDS) for 40 minutes at
room temperature. The membrane was then incubated with the
anti-cadherin (pan Cadherin antibody, Abcam, ab6529), anti-
calreticulin (Calreticulin antibody, Abcam, ab4), anti-FLAG
(FLAG M2 antibody, Sigma, F3165), anti-HA (HA antibody,
Covance, Princeton, NJ) or anti-CFTR (CFTR H-182 antibody,
Santa Cruz, sc-10747) antibody diluted in the blocking buffer at
4uC overnight. After several washing steps, membrane was
exposed to secondary HRP-conjugated antibody at room temper-
ature for 1 hour and washed before proceeding with the ECL
detection.
At the end, the PVDF membrane was always stained with the
amido black staining procedure in order to asses the efficiency of
protein transfer and check for equal loading.
The densitometric analyses of the bands has been performed by
means of the ImageJ software (NIH, USA).
Immunofluorescence
Layers of DCT cells plated on glass coverslip were fixed with
3% paraformaldehyde and permeabilized with 0.1% Triton X-
100. Non-specific binding was blocked with 5% BSA. Cells were
then incubated at the presence of the mouse anti-CFTR (CFTR
H-182 antibody, Santa Cruz, sc-10747) primary antibody at room
temperature for 1 hour, followed by Cy2 anti-rabbit (1:400
dilution, at room temperature for 1 hour) secondary antibody
incubation (Jackson Labs). Images were acquired by a confocal
microscope Leica TCS SP2 AOBS (Leica Microsystem, Heidel-
berg, Germany) provided with 636 Oil immersion objective
(1.4 NA).
FRAP
HEK293 T cells were transiently transfected (PEI method) with
YFP-CFTR and CFP-adducin WT or CFP-adducin G460W. The
experiments were performed on cells co-expressing both proteins,
48 h after-transfection, maintaining the cells at 37uC in PBS
complemented with 4.5% glucose during the confocal observation.
For imaging, YFP was excited with the 514 nm laser line and
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acquired between 525 and 600 nm, with a 636 (1.4 NA) oil
immersion objective.
YFP-CFTR photobleaching and fluorescence recovery were
analyzed in three different membrane ROIs. Fluorescence (F)
recovery was followed for 150 sec.
At each time point the mean fluorescence in the ROI (FROI(t))
was corrected for the background fluorescence (Fbg (t)) and
normalized for the mean fluorescence of a ROI that was not
subjected to photobleching (FnoPB (t)), subtracted of Fbg, to correct
for the photobleching of YFP due to the imaging procedure:
F (t)~
FROI(t){Fbg(t)
FnoPB(t){Fbg(t)
Finally, background and photobleaching-corrected F values
were normalized for the F value measured just before photo-
bleaching (FprePB), according to the equation:
Fnorm(t)~
F (t)
FprePB
To calculate the mobile fraction (Fmob%) and the half-time
constant (t1/2), each ROI fluorescence (expressed as Fnorm)
recovery was individually fitted with an exponential equation as
follows:
Fnorm(t)~A: 1{e
{B:t
 
with A=Fnorm MAX represents the F value obtained by extrap-
olation at infinite time after recovery; B= 1/t (1/s). t is the first
order rate constant for recovery and t1/2 (s) was calculated as
t: ln 2; the mobile fraction (Fmob%) was calculated according to the
following equation:
Fmob%~100:
FnormMAX{FnormMIN
1{FnormMIN
where Fnorm MIN is the first F value after photobleaching
(expressed as Fnorm).
For each experimental condition, all ROIs, t1/2 and Fmob%
values were averaged and the different populations were compared
using Student’s t-test. All data derived from three different
independent experiments.
Photoactivation Experiments
HEK cells were transiently transfected (PEI method) with
PAGFP-CFTR and CFP-adducin WT or CFP-adducin G460W.
Cell were incubated in complete medium +5 mM Ikarugamycin
(Ika cells) or complete medium +0.05% DMSO (the solvent of Ika,
control cells) for 2 hours before the experiments. All the
experiments were performed 48 h after-transfection at 37uC,
maintaining the cells in the incubation medium+HEPES 10 mM
during the confocal observation. For the imaging CFP and
PAGFP where excited with the 458 nm and the 488 nm laser
lines, respectively, and acquired in two different PMTs with the
sequential scan mode. CFP emission bandwidth: 465–490 nm,
PAGFP emission bandwidth: 500–550 nm. Pixel size: 80.2 nm,
scan speed: 1400 Hz, 8 bit intensity resolution. Photoactivation
was performed by exciting the PAGFP for 3 frames with the
405 nm laser line AOTF set to 50%, scan speed: 1400 Hz. The
fluorescence decay in the photoactivation region (ROI) was
followed for 150 s with a frame rate of 2 fr/s. Samples expressing
CFP only were used to check for possible cross-excitation of CFP
during the photoactivated PAGFP imaging with the 488 nm laser
line: no cross-excitation were measured with the acquisition setting
used. To check for possible photobleaching during the post
photoactivation time-lapse, some cells where entirely photoacti-
vated and the fluorescence were monitored for 150 s. No
photobleaching was observed during the acquisition time. The
images were analyzed with ImageJ and the obtained data with the
Excel software (Microsoft). Briefly, after the photoactivation, the
total fluorescence in the ROI (FROIt(i)) was corrected for the
background (Fbgt(i)) and for the fluorescence before the photo-
activation (FROIt(pre)2Fbgt(pre)). These corrected fluorescence
values were normalized (Fnorm), for each time point, by the ROI
total fluorescence (background- and pre-photoactivation-corrected
of the first frame after the photoactivation (FROIt(0)), according to
the formula:
Fnorm~
FROIt(i){Fbgt(i)
 
{ FROIt(pre){Fbgt(pre)
 
FROIt(0){Fbgt(0)
 
{ FROIt(pre){Fbgt(pre)
 
The data were then fitted (GraphPad Prism5 software) with
a single exponential decay curve:
Fnormt(I)~ Fnormt(0){Plateau
 
:e{K
:tzPlateau
where Plateau is the Fnorm value at infinite times and K is the rate
constant (1/s). The time constant t, expressed in (s), is the
reciprocal of K. The half-life (t1/2) is ln(2)/K. For each
experimental condition (normal medium, medium+DMSO or
medium+Ika), the half-lives of each PAGFP-CFTR+adducin WT
or PAGFP-CFTR+adducin G460W expressing cell were averaged
and the different populations were compared using Student’s t-
test. All data derived from three different independent experi-
ments.
Biotinylation Experiments
Forty-eight hours after the transient transfection of CFTR in the
HU33 and NU12 cell lines, cells were biotinylated with 1 mg/ml
EZ-Link sulfo-NHS-LC-biotin (Pierce). After blocking the bioti-
nylation reaction in PBS/100 mM glycine buffer, cells were
washed in PBS and lysed in Triton buffer (25 mM Tris-HCl,
150 mM NaCl pH 7.5, Triton 1%, BSA 0.2%). The biotinylated
surface proteins were allowed to bind to streptavidin beads (Ultra
link immobilized streptavidine, Pierce) for 24 hours at 4uC. After
three washes in lysis buffer the proteins were released from the
beads by incubation with 26 SDS loading buffer, separated by
6.5% SDS-PAGE and transferred onto PVDF membrane. The
blots were probed for the expression of CFTR using the primary
antibody anti-CFTR 24.1 (R&D Systems), and visualized by ECL.
cAMP Assay
cAMP levels were determined using a cAMP-GLO assay kit
(Promega) according to the manufacturers’ direction. Briefly, cells,
seeded 56103/well in a 96 multiwell plate 24 hours before the
assay, were washed with PBS and incubated in 20 ml of induction
buffer containing 10 mM forskolin or DMSO (forskolin solvent,
controls). Cells were then lysed in 20 ml of cAMP-GLO lysis
buffer. Lysed cell and cAMP standards were transferred to a 96-
well white wall plate, and, after a 20 min incubation in 40 ml of
cAMP detection solution, 80 ml of Kinase GLO reagent were
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added. Luminescence was measured with a Tecan F200 Pro
luminometer. cAMP concentration was calculated using the
difference between Relative Luminescence Units (RLU) values of
unstimulated and stimulated cells and the equation generated from
a cAMP standard curve, following manufacturers’ instructions.
The assays were performed on 4 independent series of samples,
and for each series every tested condition was assayed on three
distinct wells and luminescence data were normalized for protein
concentration.
Statistical Analysis
All the data are presented as mean 6 SEM. Statistical analyses
were performed using an unpaired Student’s t test or one-way or
two way ANOVA (to analyse multiple data). Statistical assessments
were done using the statistical package of Prism version 4
(GraphPad, San Diego, Calif.). The criterion for statistical
significance was a P-value ,0.05.
Results
Adducin Effects on CFTR Function: Patch-clamp Analysis
in HEK Cells
To study whether the expression of adducin has functional
consequences on CFTR activity, we performed whole-cell patch-
clamp experiments (Figure 1) on NU12 (HEK cells stably
transfected with the human wild-type adducin) and HU33 cells
(expressing the G460W mutation), transiently transfected with
a human CFTR expressing vector (pIRES2-EGFP-hCFTR) or
with the control pIRES2-EGFP vector (data not shown). In the
presence of symmetrical chloride solutions ([Cl2] = 153 mmol/L)
in the pipette and bath solution, current density Id (pA/pF, i.e. the
current intensity normalized for the cell capacitance, an index of
cell size) was not significantly different between NU12 and HU33
cells. After exposing cells to 10 mmol/L forskolin, that activates
CFTR currents by raising the levels of cyclic AMP [35], a Cl2
current was observed in the CFTR overexpressing cells, but not in
the cells transfected with the control vector (data not shown). At
maximal activation, the Id of the forskolin activated current was
significantly higher in HU33 than in NU12 cells (P,0.01). In both
cell types, the current - voltage relationship was linear and the
reversal potential (Erev) was not significantly different from 0 mV
(NU12: 0.8460.4 mV, n= 12; HU33: 1.660.3 mV, n= 14), as
expected for a chloride current in our experimental conditions
(absence of Cl2 chemical gradient). The current was inhibited by
2 mmol/L CFTR-(inh)-172, a specific inhibitor of CFTR channel
activity [36], to a value not significantly different from the value
recorded before forskolin exposure (Figure 1B–C).
The current activation curve (Figure 1D) was well fitted (least
squared method) by a sigmoid (R2 = 0.9992 and 0.9998 in NU12
and HU33 cells respectively). The slope of the regression was
significantly higher (P,0.01) in HU33
(0.04960.0019 pA6pF216s21, n = 14), compared with NU12
cells (0.02860.005 pA6pF216s21, n = 12), whereas the t50 (time
to reach the half-maximal activation) was not significantly different
between the two curves (48.7860.34 s for NU12 and
48.2960.40 s for HU33 cells).
We also investigated adducin effect on CFTR single channel
properties by performing cell-attached experiments on HU33 and
NU12 cells transiently transfected with a pIRES2-EGFP-hCFTR
expressing vector (Figure 2). In these experiments, differently from
whole-cell experiments, the imposed potential differences were
expressed as overall potential differences, determined by the
algebraic sum of the junction potential (25 mV), the holding
potential (from 2100 mV to +100 mV), and the cell membrane
potential, about 230 mV (measured with current clamp experi-
ments). A channel with a conductance of 10.560.9 pS (n = 6) and
10.860.6 pS (n= 5) was recorded in HU33 and NU12 cells,
respectively (Figure 2B). This channel was never observed in non-
transfected cells (n = 10) and had a voltage independent Po. The
Erev (the reversal potential, corrected for the junction potential and
the membrane cell potential) was not statistically different between
the two cell types (231.468.1 mV (n= 6) and 231.065.2 mV
(n= 5) in HU33 and NU12 cells respectively) and was compatible
with that expected for a chloride permeable channel (Figure 2B–
C). The channel I/V relationship showed a pronounced rectifi-
cation, differently from what observed in whole-cell experiments,
and this is presumably due to the asymmetrical chloride
concentration in cell-attached condition ([Cl2]in lower then
[Cl2]out = 151 mM). Channel density (number of active channels
per patch, 2.860.5 channels/patch, n = 6 and 1.060.4 channels/
patch, n= 5 in HU33 and NU12 cells respectively) and activity
were significantly higher in HU33 than NU12 cells (Figure 2D–E).
Accordingly, during voltage-ramp protocols, in which the voltage
of the patch was linearly changed from 2135 mV to +65 mV and
allowed to directly generate current-voltage relations, the mean
current (Iramp) recorded from patches containing one or more
active channels was significantly lower (P,0.05) in NU12 than
HU33 cells (Figure 2F). After 140 s of 10 mmol/L forskolin
exposure, the Iramp increased in both NU12 and HU33 cells but it
was still significantly higher (P,0.05) in HU33 than NU12 cells
(Figure 2G).
Since it has been reported that actin binding protein can
directly or indirectly modulate adenylate cyclase activity [37],
cAMP levels were assayed using a cAMP-GLO assay kit (Promega)
in HU33 and NU12 cells both before and after the addition of
forskolin 10 mM to the cell culture media. cAMP levels were not
significantly higher in HU33 compared to NU12 both in the
presence (217451.5677983.31 RLU (n= 4) and
113667625298.86 RLU (n= 4) in NU12 and HU33 cells re-
spectively, P.0.05) or in the absence (370905.9668154.9 RLU
(n= 4) and 205104.7625875.07 RLU (n= 4) in NU12 and HU33
cells respectively, P.0.05) of forskolin. Also cAMP concentration
measured as difference between unstimulated and stimulated cells
was not significantly different between the two cell types
(0.02402660.011712 nM (n=4) and 0.01431660.002341 nM
(n= 4) in NU12 and HU33 cells respectively, P.0.05).
CFTR Expression and Activity in MNS and MHS Cells
The data obtained with the transfected HEK cell line indicate
that the G460W mutation of adducin induces an upregulation of
CFTR activity, that is likely to be the consequence of an increased
number of active channels. To verify whether this effect was
detectable also in kidney cells isolated from an animal model, we
performed patch-clamp experiments on distal convoluted tubule
(DCT) primary cells derived from DCTs isolated from Milan
hypertensive rats (MHS), bearing a F316Y hypertensive a-adducin
mutation, and from control normotensive rats (MNS) [38].
Cell-attached patch-clamp experiments were performed on
cultured MHS and MNS primary DCT cells (Figure 3). In both
cell types we observed a Cl2 channel (Figure 3B–C) characterized
by a conductance of 7.4560.88 pS (n= 3) in MNS and
8.460.6 pS (n = 8) in MHS cells. The current reversal potential
(Erev) was 254.063.7 mV in MNS (n= 3) and 242.464.0 mV
(n= 8) in MHS and the channel open probability (Po) was voltage-
independent.
Further experiments were conducted to characterize this
channel (Figure 3D–E). After exposure to 2 mmol/L thiazolidi-
none CFTR-(inh)-172 (Figure 3E) the Po was significantly reduced
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Figure 1. G460W adducin affects CFTR whole-cell current. Chloride currents in NU12 and HU33 cells overepressing the CFTR channel (patch-
clamp, whole-cell configuration). A) Representative traces of the currents recorded in NU12 (NU) and HU33 (HU) cells in the presence of symmetrical
solutions (control), after the exposure to 10 mmol/L forskolin, and to 2 mmol/L CFTR-(inh)-172+10 mmol/L forskolin. B) Current-density (pA/pF) to
voltage (Id-V) relation recorded in NU12 cells (NU) transfected with the pIRES2-EGFP-CFTR vector. Whole-cell currents were recorded in the presence
of symmetrical chloride solutions (n = 12), 140 s after forskolin exposure (n = 12), and after CFTR-(inh)-172 inhibition (n = 12). C) Id-V relation recorded
in HU33 cells (HU) transfected with the pIRES2-EGFP-CFTR vector (n = 14). The current density was significantly higher after forskolin exposure in HU
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(P,0.01). In another set of experiments performed on selected
patches in which the channel activity was constitutively low
(Figure 3F), the Po increased from 0.0360.01 (n= 4) to 0.4960.12
(n = 4) after 5 min. exposure to 10 mmol/L forskolin. The
forskolin-activated channel was inhibited by 2 mmol/L CFTR-
(inh)-172.
This pharmacological profile, along with the channel bio-
physical properties, matched those of CFTR, whose expression
was confirmed in the MNS and MHS DCT cells by immunocy-
tochemical experiments (Figure 3G).
Similarly to what we found in HU33 and NU12 cells, even if
single channel conductance, Erev and Po did not change
significantly between MHS and MNS cells, the channel density
(Figure 4A) and activity (calculated as N.Po, Figure 4B) were
significantly (P,0.05) increased in MHS rats.
Adducin Effects on CFTR Surface Expression
In both models of kidney cells we found that the expression of
mutated adducin results in an upregulation of CFTR activity. To
assess adducin effect on CFTR expression we performed western
blot experiments on HU33 and NU12 cell lysates transiently
transfected with CFTR (Figure 5). Cadherin was probed on the
same blot to serve as loading control. CFTR antibody recognized
the fully- (band C, 160 kDa) and core-glycosylated (band B,
140 kDa) proteins [39] in NU12 cells, while only the band C was
clearly detectable in HU33 cells (Figure 5A). CFTR band pattern
in NU12 cells was similar to that of HEK293 cells non transfected
with adducin (Figure S2, panel C), suggesting that the stable over-
expression of WT adducin does not per se affect CFTR maturation.
Densitometric analysis of the bands revealed that total CFTR
(band B plus band C) was not significantly different in NU12 and
HU33 cells (Figure 5B).
To further investigate whether the plasma membrane expres-
sion level of CFTR changed in the presence of the G460W
adducin, we performed Western blot experiments on the sole
plasmamembrane protein fraction of NU12 and HU33 cells
(Figure 6). The purity of membrane preparations was checked by
monitoring cadherin and calreticulin enrichment, as reported in
Figure S2. Only one band, with a molecular weight compatible
with that of band C, was revealed in both cell types (Figure 6A),
but the protein abundance was significantly increased in HU33
cells (CFTR/cadherin = 0.8360.30, n = 6 and 6; 2.6960.72,
n = 6 in NU12 and HU33 respectively, Figure 6B). This effect was
not depending on a difference in the transfection efficiency of
HU33 and NU12 cells, as shown in Figure S2.
The increased quantity of CFTR in the plasmamembrane
fraction was confirmed also by biotinylation experiments
(Figure 6C).
CFTR and Adducin Interaction
CFTR protein is known to interact with several cytoskeletal
proteins that modulate its localization, expression, and function.
To investigate the interaction between CFTR and wild type or
mutated (G460W) a-adducin, we performed both FRET and
immunoprecipitation experiments. The FRET efficiency was
evaluated with the acceptor photobleaching method (Figure S3).
Control experiments were executed on HEK293 T cells co-
expressing ECFP and YFP-CFTR, a chimeric protein with EYFP
fused to the N-terminal of CFTR, where it doesn’t interfere with
CFTR localization and glycosylation pattern [40]. These experi-
ments allowed to estimate the aspecific FRET efficiency (FRETeff
%, in this case 20.4360.47, n = 27, Figure S3C). In cells co-
expressing YFP-CFTR and CFP-WT adducin (a chimeric protein
with ECFP fused to the N-terminal of adducin), a low FRET
signal, yet significantly higher than in control (P,0.01), was
recorded (FRETeff%: 3.6560.71, n= 40). The FRETeff % was
not significantly different from that observed when the CFP-
G460W adducin protein was expressed (FRETeff%: 3.4660.45,
n = 35). Since CFTR channel properties and expression are
modulated by forskolin, the same experiments were also
performed after cell exposure to the drug (Figure S3D), but no
significant effect was observed on FRET efficiency.
The measured FRETeff% was small, even if significantly
different from our control condition, therefore we further in-
vestigated the possible interaction between adducin and CFTR by
immunoprecipitation experiments. These assays were performed
by co-expressing in HEK293 T cells both CFTR and tagged-
adducin (Figure S4), both with a C-terminal tag (adducin-FLAG,
immunoprecipitated with an anti-FLAG antibody, Figure S4A)
and with an N-terminal tag (HA-adducin, immunoprecipitated
with an anti-HA antibody, Figure S4B). Anyway, in both
conditions, no clear specific CFTR co-immunoprecipitation was
evidenced.
Adducin Influence on CFTR Trafficking
CFTR function is correlated to its trafficking regulation. To
investigate a possible interference of mutated adducin on CFTR
trafficking and diffusional mobility in the plasma membrane, we
performed FRAP experiments. HEK293 T cells were transiently
transfected with YFP-CFTR and CFP-adducin (Figure 7) and YFP
fluorescence recovery, after YFP-CFTR photobleaching, was
followed in selected regions of interest (ROIs) comprising
membrane regions (Figure 7A). Quantitative image analysis was
used to determine the kinetics of fluorescence recovery after
photobleaching (Figure 7A–B). The percentage fluorescence
recoveries, generally interpreted as the fraction of mobile GFP-
labeled molecules (Fmob%), was 67.2064.84 (n = 38 experiments
on cells from 3 transfection batches) for YFP-CFTR in the
presence of WT adducin, a value comparable to those already
reported for overexpressed-CFTR [41]. The mobility is likely to
reflect both CFTR recycling and membrane internal movements,
since the recovery in the lateral portion of the selected ROIs was
faster than that in the central part of the ROI (central t1/2
28.8863.28 s; lateral t1/2 18.4161.55 s, n = 26 experiments on
cells from 3 transfection batches, P,0.01). The co-expression with
YFP-CFTR of the G460W variant significantly reduced the
Fmob% (53,1863,88, n= 42 experiments on cells from 3 trans-
fection batches, P,0.05). The average values half-time constant
(t1/2) for WT and G460W adducin were not significantly different
(WT 28.1762.11 s, n = 38 experiments on cells from 3 trans-
fection batches; G460W 23.6361.47 s, n = 42 experiments on
cells from 3 transfection batches).
To further investigate CFTR mobility and especially the
influence of adducin on its trafficking we also performed
photoactivation experiments, by transiently co-expressing
PAGFP-CFTR (CFTR fused to a N-t photoactivable EGFP
protein) and CFP-adducin (WT or G460W) in HEK cells. Also in
this case we focused on the plasma membrane region, by
versus NU cells (P,0.01). D) Activation kinetics of the CFTR-mediated chloride current in NU12 and HU33 cells (NU and HU) transfected with the
pIRES2-EGFP-CFTR vector. Activation currents values were interpolated by sigmoid curves, that were significantly different in HU33 versus NU12 cells
(P,0.01).
doi:10.1371/journal.pone.0052014.g001
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Figure 2. G460W adducin affects CFTR single channel activity. Chloride currents in NU12 and HU33 cells overexpressing the CFTR channel
(patch-clamp, cell-attached configuration). A) Representative single-channel traces at positive or negative potentials as indicated, recorded in NU12
(NU, left panel) or HU33 cells (HU, right panel). The dotted line corresponds to the closed level. B) Single channel current-voltage (I–V) relation for
CFTR in NU12 and HU33 cells (n = 5 and 6). C) Open probability (Po) versus potential plots for CFTR channels recorded in NU12 (n = 5) and HU33 cells
(n = 6). D) Channel density in NU12 (n = 5) and HU33 (n = 6) cells (N= channel density, n= total number of seals). P,0.05. E) Channel activity, measured
as N multiplied by channel open probability (Po), versus membrane potential for NU12 (n = 5) and HU33 (n = 6) cells. P,0.05. F) Mean current
recorded during voltage protocol consisting of ramps from 2135 mV to +65 mV, applied to cell-attached patches at a rate of 0.5 mV/ms. The I/V
represents the mean current of 10 ramp protocols from 5 and 6 patch of NU12 and HU33 cells respectively. In the box representative single ramp
records are reported for NU12 (upper ramp) and HU33 (lower ramp). G) Mean current recorded in the same condition as in F, after 3 minutes
exposure to 10 mmol/L forskolin.
doi:10.1371/journal.pone.0052014.g002
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photoactivating PAGFP-CFTR in ROIs comprising membrane
portions and monitoring the decrease in time of the fluorescence
(Figure 8A). The half time constant (t1/2), calculated by fitting the
resulting curves with an exponential decay function, was
21.1361.80 s (n = 30 experiments on cells from 3 transfection
batches) in the presence of WT-adducin and was significantly
(P,0.05) increased when G460W adducin was expressed (t1/
2 = 28.3563.12, n = 29 experiments on cells from 3 transfection
batches, Figure 8C), thus confirming that the mutation of adducin
causes a reduced CFTR mobility in the membrane region. The
effect of G460W adducin on PA-CFTR mobility was similar, even
if less intense, to that obtained by treating WT adducin transfected
cells with ikarugamycin (Figure 8B, t1/2 = 22.0761.40, n= 20
experiments on cells from 3 transfection batches for control; t1/
2 = 54.0468.57, n = 19 experiments on cells from 3 transfection
batches for IKA; P,0.05), that acts as a general inhibitor of
clathrin-coated pit-mediated endocytosis and has been used in
endocytosis study [42,43].
Discussion
Several studies proved that CFTR activity is influenced by actin
cytoskeleton and its polymerization state [26]. In this study we
demonstrate that in G460W a-adducin expressing cells and in
isolated DCT cells of MHS rats the activity of the CFTR channel
increases as well.
The expression of the hypertensive mutation of adducin leads to
a functional modification of CFTR activity, as observed in the
Figure 3. CFTR channel in MNS and MHS DCT cells. A) Representative traces of the rat 8 pS chloride channel recorded at positive or negative
potentials in DCT cells isolated from 11 MHS and 16 MNS rats. 0 indicates the closed level. B) Mean current-voltage (I-V) curve of CFTR in MNS (n = 3)
and MHS DCT cells (n = 8). C) Open probability (Po) curve of CFTR in MNS (n = 3) and MHS DCT cells (n = 8). D) Representative trace showing inhibition
by CFTR-(inh)-172. E) Histograms representing the channel open probability (Po) before or after 2 mmol/L CFTR-(inh)-172 exposure (n = 4). **P,0.01.
F) Channel open probability (Po) after 10 mmol/L forskolin and 2 mmol/L CFTR-(inh)-172 exposure (n = 4). G) Confocal images showing CFTR
expression in MNS and MHS DCT cells. CFTR is located both in the plasma membrane and in intracellular vesicles. Primary antibody: anti-CFTR;
secondary antibody: Cy2 anti-rabbit. Blue: nuclei DAPI staining. Scale bar is 20 mm.
doi:10.1371/journal.pone.0052014.g003
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patch-clamp experiments performed on HU33/NU12 stably
transfected HEK cells. The forskolin activated whole-cell CFTR
current recorded at maximal activation was significantly (P,0.05)
higher in HU33 cells, expressing the hypertensive variant of
adducin, than in NU12 cells, expressing the WT variant. The
increase in current density at maximal activation, along with the
observation that the slope of the activation, but not the t50,
significantly increased, suggests a higher CFTR density in the
plasmamembrane of G460W adducin expressing cells. The single
channel experiments evidenced that the mutation of adducin
associates with an increased channel activity both before and after
forskolin exposure and CFTR activation. Measurements of
intracellular cAMP level indicate that this is not due to an
upregulation of the cAMP pathway in HU33 cells. Consistently
with this hypothesis, the experiments performed on MNS/MHS
rats indicate that this effect is reproducible also in cultured primary
DCT cells, isolated from the animal hypertensive models. DCT is
involved in hypertension maintenance in the MHS rats, in which
the expression and activity of both Na+-Cl2 cotransporter and
ClC-K increase [11], and the Na+/K+ pump is upregulated [12].
The experiments evidenced that the mutation of adducin in MHS
rat DCT cells correlates with an increased CFTR channel density
and activity, suggesting that CFTR could be directly or indirectly
involved in the general alteration of renal ion transport in essential
hypertension. Nowadays, despite the relatively high expression of
CFTR in the kidney, its role in this organ is still elusive [19] and it
has been hypothesized that CFTR could not only secrete but also
absorb Cl2 across the apical membrane of distal tubules, at least
when Na+ absorption is stimulated and the apical membrane
potential depolarized [22], therefore contributing to the increased
transcellular NaCl reabsorption observed in hypertension. It is
possible that in the kidney its regulatory role might be more
relevant than its activity as a chloride channel. It has recently been
proposed that its membrane localization could influence both
cytoskeletal organization and compartmentalization of signaling
molecules such as cAMP and PKA in the subcortical compartment
[44]. Moreover, CFTR is also known as a modulator of the activity
of others transport systems, such as the ROMK K+ channel and
the ENaC Na+ channel [19,45]. Several studies have demonstrat-
ed in vivo an inverse relation between the putative CFTR levels
and the expression of ENaC [46]. At a first glance, these
observations are difficult to reconcile with the hypothesis that an
increase of CFTR in the membrane would result in an increase of
the NaCl intake, but could rather suggest that the increased
surface expression of CFTR could help in counteracting the
pathologically increment of salt uptake in the hypertensive
subjects. Yet, the interaction between CFTR and ENaC seems
to be more complex and dependent on the cell type: the activation
of CFTR inhibits ENaC in airways cells [46,47] and colonic cells
[48], whereas it is accompanied by the concomitant activation of
ENaC in absorptive sweat gland cells [49], in CCD kidney cells
Figure 4. CFTR density and activity. A) Channel density in MNS
(n = 35) and MHS (n = 22) DCT cells (N= channel density, n= total
number of seals). *P,0.05. B) Channel activity (NxPo, measured as N
multiplied by channel Po) versus membrane potential (V) for MNS
(n = 35) and MHS (n = 22) channels. *P,0.05 when comparing the two
data sets.
doi:10.1371/journal.pone.0052014.g004
Figure 5. Expression of total CFTR protein (fully and core
glycosylated) in NU12 and HU33 cells. A) Western blot analysis of
CFTR expression in NU12 and HU33 cells transiently transfected with
the pcDNA3-CFTR vector; arrows indicate the core-glycosylated (band
B) and fully glycosylated (band C) forms of CFTR. The blot was probed
with anti-CFTR antibody (top panel) and anti-cadherin antibody (lower
panel). B) Densitometric analysis of the ratio of total CFTR (band
C+band B)/cadherin band intensities (OD CFTR/OD Cad: n = 7 for NU12,
n = 6 for HU33); ns=non significative. Only samples showing both CFTR
and cadherin clear signals were considered for the quantitative analysis.
doi:10.1371/journal.pone.0052014.g005
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[50] and in MDCK cells [51]. As pointed out by Kunzelmann
[52], the inhibitory effect of CFTR in some preparations may be
due to the rise it produces in intracellular Cl2 concentration rather
than to a direct molecular interaction of CFTR with ENaC.
Therefore, in epithelial cells, that are actively involved in Cl2
secretion and absorption, and where chloride is maintained above
its electrochemical equilibrium value, the effect of activating
CFTR (e.g., by cAMP, forskolin, or cholera toxin) would result in
a fall in intracellular Cl2 concentration, and therefore in ENaC
activation [52]. In agreement with this observation, Xie and
Shafer [51] demonstrated that the treatment with cAMP
stimulates Cl2 secretion via cystic fibrosis transmembrane
conductance regulator as well as ENaC-mediated Na+ absorption
in MDCK cells. This could be in agreement with a lack of a kidney
phenotype in cystic fibrosis patients [53,54], in which CFTR
activity is compromised, but chloride intracellular concentration
could be modulated by the plethora of chloride channels [55] and
transporters [56] that are active in kidney cells.
An involvement of CFTR in the renal regulation of extracellular
fluid volume (ECFV) and, hence, in transepithelial transport, is
additionally suggested by the observation that ECFV regulatory
hormones, such as vasopressin or thyroid hormone, increase
CFTR expression in the kidney [57,58]. Actually it has already
been proposed that an enhancement of CFTR activity could be
involved in hypertension [54,59,60] and in hypertension related
pathologies, such as Liddle syndrome [19,50].
As a whole, additional studies are needed to better clarify the
link between CFTR and kidney pathophysiology.
In this work we tried to further investigate the molecular
mechanisms by which adducin could regulate CFTR activity.
In HEK cells overexpressing adducin, the measured increased
activity of CFTR is paralleled by an altered processing efficiency of
CFTR in the G460W adducin expressing cells; Western blot
experiments revealed an increase of the ratio between the fully
glycosylated band C and the core-glycosylated band B expression
in HU33 compared with NU12 cells. The fully glycosylated band
C of CFTR represents its mature form, predominantly located in
the plasmamembrane and in the recycling submembrane vesicles,
while band B represents the immature form of CFTR typical of
the endoplasmic reticulum [39,61]. The increase in the amount of
plasmamembrane band C does not seem to be a consequence of
a change in the total amount of CFTR (band B+C, Figure 5) and
could be either due to an increase in the glycosylation efficiency or
to a reduction of endocytosis, leading to a reduced turnover and to
a longer retention of mature CFTR into the membrane. Channel
glycosylation influences CFTR turnover in the post-endoplasmic
reticulum compartments, with the fully glycosylated channel being
more stable [62,63], whereas it does not influence channel activity
[62]. Therefore the enhancement of channel glycosylation
observed in HU33 cells could lead to the observed increase of
channel surface expression, revealed both by the Western blot
experiments performed on the plasma membrane protein fraction
and by biotinylation experiments (Figure 6), resulting in an
increased number of active channels. Anyway, while no reports
link adducin to glycosylation pathways, it has already been
demonstrated that the expression of the mutated adducin reduces
the endocytosis of Na+/K+-ATPase [8,14] and of AQP4 water
channel [64], suggesting that a similar mechanism is more likely to
be directly involved also in the observed enhancement of CFTR
surface expression and channel density.
To further investigate this point, we focused on CFTR-
a adducin interaction and CFTR trafficking.
FRET experiments demonstrated a faint but significative
FRETeff that might imply a close vicinity (in the nm range)
between CFTR and adducin. The FRETeff was not significantly
changed in the presence of the mutated G460W adducin variant
both in the basal state or after the channel activation with
forskolin. Anyway, immunoprecipitation experiments failed to
Figure 6. Expression of CFTR in the plasmamembrane fraction in NU12 and HU33 cells. A) Western blot analysis of CFTR expression in
NU12 and HU33 cells transiently transfected with the pcDNA3-CFTR vector; only one band at a molecular weight compatible with that of band C
(,160 kDa) is visible in the plasmamembrane fraction. The blot was probed with anti-CFTR antibody (top panel) and anti-cadherin antibody (lower
panel). B) Densitometric analysis of the ratio of plasmamembrane CFTR/cadherin band intensities (OD CFTR/OD Cad, n = 6). *P,0.05. C) Western blot
analysis of biotinylated CFTR in NU12 and HU33 cells transiently transfected with the pcDNA3-CFTR vector. CFTR signal (anti-CFTR antibody) in cell
lysates (lysates, upper panel) and in the cell surface fraction (surface, lower panel) are reported. Only one band compatible with band C is detectable
in the cell surface fraction. No biotinylation condition served as control (NU12 ctrl, HU33 ctrl).
doi:10.1371/journal.pone.0052014.g006
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Figure 7. G460W adducin influences CFTR trafficking: FRAP experiments. A) Cell images from a FRAP experiment: YFP-CFTR signal in
a HEK293 T cell over-expressing CFP-WT adducin (Add-WT, upper panels) or CFP-G460W adducin (Add-G460W, lower panels) before YFP
photobleaching (pre PB) and at different time-points after the photobleaching (post PB t = 0 s, 20 s, 50 s); on the right the corresponding CFP-adducin
signal (Add) is reported for each condition. In the pre-photobleaching images three membrane ROIs are shown. Scale bar is 5 mm. The graph shows
the kinetics of CFTR-YFP fluorescence recovery after photobleaching in presence of the CFP-adducin WT or G460W mutated variant. B) Mean CFTR
mobile fraction percentage (Fmob%) and mean half-life constants (t1/2) of HEK cells over-expressing YFP-CFTR and CFP-WT adducin (n = 38) or CFP-
G460W adducin (n = 42). *P,0.05.
doi:10.1371/journal.pone.0052014.g007
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reveal a clear co-immunoprecipitation of CFTR with adducin,
suggesting that, if any, the possible interaction between the two
proteins is likely to be feeble and unstable as already reported for
the interaction between CFTR and actin mediated by interme-
diate cytoplasmic proteins [41].
Direct binding is not the only way by which adducin could
modulate CFTR channel activity and affect its surface expression.
CFTR, as adducin, forms a submembrane complex with several
proteins, comprising actin [5,35] or AP-2 [14,65]. Adducin
mutations could act by altering CFTR traffic, both through the
modulation of cytoskeleton dynamics [26] and/or through
affecting of AP2-m2 phosphorylation [65], as already reported
for the Na+/K+ pump [8,14]. To investigate this point we
performed both FRAP and photoactivation experiments. In both
cases we found a rather high mobility of CFTR in the ROIs
comprising plasmamembrane portions (70–52% Fmob% for
FRAP), with a comparable t1/2. The values of Fmob% are similar
to those obtained in other studies [41,66] and the relatively high
Figure 8. G460W Adducin influences CFTR trafficking: photoactivation experiments. A) Cell images from a photoactivation experiment:
PAGFP-CFTR signal in a HEK293 T cell over-expressing CFP-WT adducin in control conditions (contr, upper panels) or in presence of ikarugamycin (ika,
lower panels), an inhibitor of endocytotic recycling. Different time-points after photoactivation are shown (t = 0 s, 20 s, 50 s), together with the bright
field images and the CFP-adducin signals (Add). In the bright field images the membrane ROIs are evidenced. Scale bar is 5 mm. B) Representative
traces showing the kinetics of fluorescence decay after PAGFP-CFTR photoactivation in HEK cells over-expressing CFP-WT adducin exposed to
ikarugamycin (ika, n = 19) or in control conditions (contr, n = 20). Mean half-lives (t1/2) are shown. *P,0.05. C) Representative traces showing the
kinetics of fluorescence decay after PAGFP-CFTR photoactivation in HEK cells over-expressing CFP-adducin WT (WT, n = 30) or G460W mutated
(G460W, n = 29) variant. Mean half-life constants (t1/2) are shown. *P,0.05.
doi:10.1371/journal.pone.0052014.g008
Adducin Modulation of CFTR Activity
PLOS ONE | www.plosone.org 13 December 2012 | Volume 7 | Issue 12 | e52014
mobility, especially of WT-CFTR, is likely to be a consequence of
overexpression, as already proposed [66,67]. Moreover, at least
part of the measured CFTR mobility is depending on lateral
membrane diffusion, as proven, in the case of the FRAP
experiments, by the lower t1/2 measured for the lateral portions
of the ROIs, compared to the central ones. Yet, both FRAP and
photoactivation experiments indicate that CFTR is more and/or
longer retained in the membrane area when mutant adducin is co-
expressed, according to the hypothesis that the mutations of
adducin alter CFTR membrane mobility and apparently lower its
membrane turnover. The effect of G460W adducin on PA-CFTR
t1/2 was similar, even if less intense, to that obtained by treating
WT adducin transfected cells with ikarugamycin (Figure 8B),
suggesting that clathrin-coated pit-mediated endocytosis could be
negatively affected by the mutation of adducin, as already reported
for other transporters. The experiments cannot anyway exclude
that also an altered actin cytoskeleton architecture might be
involved. Actually, explorative immunofluorescence experiments
confirm, in accordance with other reports [9], that the cytoskel-
eton of HEK cells seems to be affected by the expression of
mutated adducin (Figure S5), presenting thicker and more
abundant actin fibers, suggesting an increased cytoskeletal stiffness.
Subcortical actin cytoskeletal is believed to be important for the
anchoring of membrane proteins, thus limiting random lateral
diffusion in the membrane, helping compartmentalization and also
influencing the activity of ion channels and transporters [9,44,68].
Since CFTR is known to be subjected to clustering [69] and
retention in zones of transient confinement [66], the state of the
actin network is likely to impact on its mobility. Therefore, the
retention of CFTR in the membrane area might be the
consequence both of a reduced endocytosis and of an increased
actin cytoskeletal stiffness induced by the mutated forms of
adducin, that could exert an inhibitory effect on membrane
protein lateral mobility [70,71] and traffic [8,72].
In conclusion, despite several hypotheses concerning CFTR
involvement in hypertension, our study is, to our knowledge, the
first to demonstrate a connection between CFTR and adducin,
showing that channel activity is increased in isolated DCT cells of
hypertensive MHS rats and in HEK cells overexpressing an
hypertensive variant of adducin. In renal cell models, adducin
mutations are likely to influence CFTR activity by affecting its
membrane turnover, leading to a retention of the channel in the
plasmamembrane.
Since CFTR is known to modulate the activity of many others
transport systems, the increased surface expression of the channel
could have consequences on the whole network of transport in the
kidney cells. Further studies and additional analyses, either genetic
or functional, on hypertensive patients as well, will help to fully
understand the importance of CFTR in the modification of renal
NaCl absorption in vivo.
Supporting Information
Figure S1 Adducin expression in NU12 and HU33 cells.
A) Western blot analysis of HA-adducin expression in NU12 (Nu1,
Nu2) and HU33 (Hu1, Hu2) cells, compared with non transfected
HEK cells (NT1, NT2). Two independent preparations are shown
for each condition. The blot was probed with anti-HA antibody.
B) Confocal images showing HA-adducin expression in NU12
(NU) and HU33 (HU) cells, together with bright field images.
Primary antibody anti-HA, secondary antibody Alexa 488 anti-
mouse; in the control condition (contr) the primary antibody was
omitted. Scale bar is 10 mm.
(TIF)
Figure S2 Assessment of HU33/NU12 transfection effi-
ciency and plasma membrane protein enrichment. A)
Confocal images showing CFTR expression in HU33 (upper
panels) and NU12 (lower panels) cells, transfected with pcDNA3-
CFTR plasmid (HU CFTR, NU CFTR, left), non transfected NU
and HU cells (HU NT, NU NT, right) served as control. Primary
antibody: anti-CFTR, secondary antibody: Alexa 568 anti-mouse;
nuclei are stained in blue (DAPI). Scale bar is 10 mm. Histograms
illustrate the percentage of transfected NU12 (NU) and HU33
(HU) cells; showing no significant differences in transfection
efficiency (n = 11). B) Transfection efficiency was also assessed with
the Renilla luciferase reporter assay. NU12 and HU33 cells were
cotransfected with pcDNA3-CFTR and pRL-TK (renilla lucifer-
ase reporter gene under the control of thymidine kinase promoter)
plasmids, thus allowing the evaluation of cells transfection
efficiency. The two histograms show luciferase activity normalized
for the number of cells (AU luminometry/N cells, left, n = 15) or the
total protein amount (AU luminometry/mg prot, right, n = 20) in
NU12 (NU) and HU33 (HU) cells; no significant differences
between the two cell types are revealed. C) Western blot analysis of
CFTR expression in NU12 (NU12), stably transfected with WT
adducin and control HEK293 (HEK293) cells, non transfected
with adducin. Both cell types were transiently transfected with the
pcDNA3-CFTR vector and probed with an anti-CFTR antibody.
Both the 140 kDa core-glycosylated (band B) and the 160 kDa
fully glycosylated (band C) forms of CFTR are detectable in the
two cell types. D) Western blot analysis to assess plasma membrane
separation efficiency. Western blot shows cadherin (plasma
membrane marker; upper blot) enrichment in the plasma
membrane, compared to calreticulin (endoplasmatic reticulum
marker; lower blot). The upper blot was probed with anti-cadherin
antibody, the lower blot was probed with anti-calreticulin
antibody. The same quantity of proteins (25 mg) was loaded for
all fractions. PM: plasmamembranes, Lys: lysate, Cyt: cytoplasmic
fraction; LP: lower phase, formed by the remaining total
membrane proteins, after the extraction of the plasma membrane
fraction.
(TIF)
Figure S3 Interaction between adducin and CFTR:
FRET experiments. The acceptor photobleaching method
was used to obtain the FRET efficiency. A) Cell images of the CFP
(CFP, upper panel) or YFP (YFP-CFTR, lower panel) channel
before (pre-bleach) and after (post-bleach) the YFP photobleaching
and FRET efficiency images (FRET) for HEK cells overexpressing
CFP and YFP-CFTR (control). Scale bar is 10 mm. B) Cell images
of the CFP (Add-CFP, upper panel) or YFP (YFP-CFTR, lower
panel) channel before and after the YFP photobleaching and
FRET efficiency images (FRET) for HEK cells overexpressing
CFP- adducin WT and YFP-CFTR. Scale bar is 10 mm. C) FRET
efficiency (FRETeff %) measured in control cells (CFP+Y-CFTR,
n = 27) and in cells overexpressing YFP-CFTR and the CFP-
adducin WT (Y-CFTR+C-Add WT, n = 40) or the G460W mutated
variant (Y-CFTR+C-AddG460W, n = 35). **P,0.01. D) FRET
efficiency (FRETeff %) measured after 10 mmol/L forskolin
exposure in control cells (CFP+Y-CFTR, n = 4) and in cells
overexpressing YFP-CFTR and the CFP-adducin, WT (Y-
CFTR+C-Add WT, n = 11) or G460W mutated variant (Y-
CFTR+C-AddG460W, n = 9). *P,0.05.
(TIF)
Figure S4 Interaction between adducin and CFTR:
immunoprecipitation experiments. A) Immunoprecipita-
tion experiment on HEK cells cotransfected with pcDNA3-CFTR
and pcDNA3.1-WT adducin-FLAG (C-terminal FLAG tag, Add-
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FLAG); pcDNA3-CFTR and pFLAG-CMV4-BAP (bovine alkaline
peroxidase, FLAG-BAP) cotransfection served as control. CFTR
signal (upper panel; anti-CFTR antibody) and FLAG signal (lower
panel; anti-FLAG antibody) in cell lysates (Lys), flow through (FT)
and five sequential 40 ml eluates (E1–E5) are shown. B)
Immunoprecipitation experiments on HEK cells cotransfected
with pcDNA3-CFTR and pcDNA3.1-HA-WT adducin (N-
terminal HA-tag, HA-Add). pcDNA3-CFTR and empty pFLAG-
CMV4 plasmid cotransfection served as control (ctrl). CFTR signal
(upper panel; anti-CFTR antibody) and HA signal (lower panel;
anti-HA antibody) in cell lysates (Lys) and eluates (E) from 2 and 24
hours incubation with anti-HA agarose affinity gel are shown.
Subscripts A and B refer to two independent preparations.
(TIF)
Figure S5 Actin and adducin staining in NU12 and HU33
cells. Confocal images showing actin (Act, left) and adducin (Add,
right) in HU33 (HU, upper panels) and NU12 (NU, lower panels)
cells. Primary antibody: anti-HA; secondary antibody: Alexa
488 anti-mouse. Actin fibers were stained with Alexa 568
Phalloidin. Scale bar is 10 mm.
(TIF)
Text S1 Supplementary methods. Additional methodolog-
ical information concerning the results presented in the supple-
mentary figures, i.e. evaluation of transfection efficiency, fluores-
cence resonance energy transfer (FRET) experiments,
immunoprecipitation, HA-adducin and actin staining of HU33/
NU12 cells.
(DOC)
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